SecBot SecBot
Biotech Drug Report Generated Nov 20, 2026

certepetide

LSTA·Lisata Therapeutics, Inc.
BEARISH
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
Certepetide is in Phase 2 clinical development with no registered Phase 3 trial underway. Given the company's strategic pivot to cardioendocrine diseases, the timeline to potential approval is highly uncertain and likely several years away, if pursued at all.
Why 3/10
No upcoming binary catalyst (PDUFA date, pivotal readout, or regulatory decision) is scheduled for certepetide in the next ~12 months. The drug is now a legacy asset after Lisata's September 2026 acquisition of Marea Therapeutics pivoted the company to cardioendocrine diseases. ImpactScore is 3 because certepetide is an approved-stage-adjacent program with no imminent binary event at a company that has refocused elsewhere.
Actionable Insight BEARISH

Certepetide is now a legacy pipeline asset for Lisata, which has pivoted to cardioendocrine diseases via the Marea acquisition. No upcoming binary catalyst (PDUFA, pivotal readout) is scheduled for certepetide. The final ASCEND Phase 2b data, expected Q1 2026, may have been released without fanfare given the corporate transformation. Watch for any out-licensing or partnership deal for certepetide, or its deprioritization in future pipeline updates.

Price Chart

Loading chart...

Executive Summary

Certepetide (formerly LSTA1/CEND-1) is an investigational iRGD cyclic peptide designed to enhance tumor penetration of co-administered anti-cancer drugs. It showed encouraging Phase 2b ASCEND trial data in metastatic pancreatic cancer, with improved overall survival and complete responses versus placebo. However, after a tumultuous 2026 that included a failed Kuva Labs merger and a subsequent reverse merger with Marea Therapeutics, Lisata has pivoted from oncology to cardioendocrine diseases. Certepetide is now a legacy asset; the company's lead programs are MAR001 (Phase 2b for severe hypertriglyceridemia) and MAR002 (Phase 2 for acromegaly). No Phase 3 trial for certepetide has been initiated, and no upcoming binary catalyst is scheduled. The stock trades near its 52-week low with a reverse split incoming.

How It Works

Certepetide is a synthetic cyclic peptide (a small protein-like molecule) that exploits a natural transport system found only in solid tumors. When injected into the bloodstream, it activates a pathway that allows co-administered chemotherapy or other anti-cancer drugs to more deeply penetrate and accumulate inside tumors, rather than just reaching the tumor surface. It also changes the tumor's surrounding environment (microenvironment) to make it more vulnerable to immune-based therapies.

Trial Status

The Phase 2b ASCEND trial (Cohorts A and B) in metastatic pancreatic cancer reported positive preliminary data in 2025. Final data from both cohorts was anticipated for Q1 2026. A separate Phase 2 trial in advanced solid tumors (cholangiocarcinoma) has been completed. A Phase 1/2a CENDIFOX trial in resectable/borderline resectable pancreatic cancer is ongoing. Phase 3 preparations were discussed in 2025 but no Phase 3 trial has been initiated as of November 2026.

The Two-Sided Case

▲ Bull Case5
Certepetide showed encouraging Phase 2b ASCEND trial data: Cohort A median overall survival of 12.68 months vs 9.72 months for placebo, with 4 complete responses vs 0, and Cohort B corroborated with positive signals in progression-free survival and objective response rate.
The drug has a novel mechanism as an iRGD cyclic peptide that activates a tumor-specific active transport pathway, potentially enhancing delivery of a wide range of anti-cancer drugs including immunotherapies and ADCs.
Lisata continues to build IP protection: a composition of matter patent (protection to 2040) was granted in July 2025, and a new method of use patent was granted in October 2026, suggesting ongoing commitment to the asset.
Catalent (licensing partner) reported positive preclinical data in November 2025 for certepetide as part of antibody-drug conjugate combinations, opening potential partnership or royalty opportunities.
The company now has a strong cash position following the $225 million private placement concurrent with the Marea acquisition, providing resources to potentially advance certepetide or seek partnerships.
▼ Bear Case5
Certepetide is no longer Lisata's lead asset; after the September 2026 Marea acquisition, the company's focus shifted to cardioendocrine diseases (MAR001, MAR002), and pre-transaction Lisata shareholders retained only ~2.39% of the combined entity, making certepetide a minor legacy program.
The planned Phase 3 development for certepetide, which management discussed in early 2025, appears to have been deprioritized or shelved following the failed Kuva merger and the Marea reverse merger.
Both HC Wainwright (to Neutral) and Brookline Capital (to Hold) downgraded the stock in 2026, and analyst coverage is now stale (last action May 2026). The stock trades at $0.91, near its 52-week low of $0.86.
The Qilu Pharmaceutical license for certepetide was mutually terminated in January 2026, removing a potential Asia commercialization partner and milestone stream.
A 1-for-15 reverse stock split was announced effective November 23, 2026, to maintain Nasdaq listing, signaling distress at the pre-split share price level.

Upcoming Catalysts

  • Potential out-licensing or partnership announcement for certepetide
  • Possible publication of final ASCEND Phase 2b data
  • Pipeline update from Lisata clarifying certepetide's strategic priority

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Lisata Therapeutics, Inc. Press Release LSTA ·Originating report

Sources · 11

Hover a chip for the title
1 markets.financialcontent.com2 markets.financialcontent.com3 nasdaq.com4 msn.com5 markets.businessinsider.com6 streetinsider.com7 manilatimes.net8 cancernetwork.com9 marketscreener.com10 markets.financialcontent.com11 morningstar.com